Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2020-03-17 Earnings Release
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 17, 2020, reporting the company's financial results for the period ended December 31, 2019. It specifically states that the full text of the press release is furnished as an exhibit and incorporated by reference. The document itself is short (4092 characters) and primarily serves as a current report announcing the earnings release rather than containing detailed financial statements or analysis. According to the rules, such a document is classified as an Earnings Release (ER) because it is the initial announcement of quarterly/periodical financial results with key highlights only, not a full annual or interim report. Therefore, the appropriate classification is ER with high confidence.
2020-03-17 English
10-K
Annual Report FY 2019
2020-03-17 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Proxy Statement filed on Schedule 14A with the SEC, related to the 2020 Annual Meeting of Stockholders of Novus Therapeutics, Inc. It includes detailed information about the meeting agenda, board of directors, corporate governance, executive compensation, and voting instructions. It is not a report of voting results, nor an announcement of a report publication. It is not a financial report like an Annual Report (10-K) or Interim Report (IR). It is a solicitation document sent to shareholders to provide information and request votes for the annual meeting. Therefore, it fits the definition of Proxy Solicitation & Information Statement (PSI). The document length and content confirm it is the full proxy statement, not just a notice or announcement.
2020-03-13 English
Director's Dealing 2020
Director's Dealing
2020-02-25 English
Director's Dealing 2020
Director's Dealing
2020-02-25 English
AMENDMENT NO. 3
Major Shareholding Notification
2020-02-25 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.